Skip to main content
Top
Published in: Current Obesity Reports 3/2016

01-09-2016 | Health Services and Programs (AG Tsai, Section Editor)

Investing in Obesity Treatment: Kaiser Permanente’s Approach to Chronic Disease Management

Authors: Adam G. Tsai, Trina Histon, W. Troy Donahoo, Shahid Hashmi, Sameer Murali, Peggy Latare, Lajune Oliver, Jennifer Slovis, Sarah Grall, David Fisher, Loel Solomon

Published in: Current Obesity Reports | Issue 3/2016

Login to get access

Abstract

Kaiser Permanente, an integrated health care delivery system in the USA, takes a “whole systems” approach to the chronic disease of obesity that begins with efforts to prevent it by modifying the environment in communities and schools. Aggressive case-finding and substantial investment in intensive lifestyle modification programs target individuals at high risk of diabetes and other weight-related conditions. Kaiser Permanente regions are increasingly standardizing their approach when patients with obesity require treatment intensification using medically supervised diets, prescription medication to treat obesity, or weight loss surgery.
Literature
2.•
go back to reference Dietz WT, Solomon LS, Pronk N, et al. An integrated framework for the prevention and treatment of obesity and its related chronic diseases. Health Aff. 2015;34:1456–63. This paper describes how various health care organizations and communities have used a comprehensive strategy to prevent and treat obesity.CrossRef Dietz WT, Solomon LS, Pronk N, et al. An integrated framework for the prevention and treatment of obesity and its related chronic diseases. Health Aff. 2015;34:1456–63. This paper describes how various health care organizations and communities have used a comprehensive strategy to prevent and treat obesity.CrossRef
3.
go back to reference Cheadle A, Schwartz PM, Rauzon S, Beery WL, Gee S, Solomon L. The Kaiser Permanente Community Health Initiative: overview and evaluation design. Am J Public Health. 2010;100(11):2111–3.CrossRefPubMedPubMedCentral Cheadle A, Schwartz PM, Rauzon S, Beery WL, Gee S, Solomon L. The Kaiser Permanente Community Health Initiative: overview and evaluation design. Am J Public Health. 2010;100(11):2111–3.CrossRefPubMedPubMedCentral
4.
go back to reference Cheadle A, Schwartz PM, Rauzon S, et al. Using the concept of “population dose” in planning and evaluating community-level obesity prevention initiatives. American Journal of Evaluation. 2013;34(1):71–84.CrossRef Cheadle A, Schwartz PM, Rauzon S, et al. Using the concept of “population dose” in planning and evaluating community-level obesity prevention initiatives. American Journal of Evaluation. 2013;34(1):71–84.CrossRef
5.
go back to reference Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRefPubMedCentral Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRefPubMedCentral
6.
go back to reference Diabetes Prevention Program Outcomes Study Research Group. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30:46–55.CrossRef Diabetes Prevention Program Outcomes Study Research Group. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30:46–55.CrossRef
7.•
go back to reference Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102–38. This is the updated obesity treatment guidelines for using behavioral methods and surgery to treat obesity. The use of medications to treat obesity is outlined in reference 10 below.CrossRefPubMed Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102–38. This is the updated obesity treatment guidelines for using behavioral methods and surgery to treat obesity. The use of medications to treat obesity is outlined in reference 10 below.CrossRefPubMed
9.
go back to reference Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621–8.CrossRefPubMed Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621–8.CrossRefPubMed
10.
go back to reference Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin Sci (London). 2013;124:231–41.CrossRef Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin Sci (London). 2013;124:231–41.CrossRef
11.•
go back to reference Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–62. This guideline is the first ever to describe how to use medications to treat obesity and also how to prescribe medications for other medical conditions to reduce the risk of weight gain.CrossRefPubMed Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–62. This guideline is the first ever to describe how to use medications to treat obesity and also how to prescribe medications for other medical conditions to reduce the risk of weight gain.CrossRefPubMed
13.
go back to reference Li RA, Fisher DP, Dutta S, O’Brien RM, Ackerson LM, Sorel ME, et al. Bariatric surgery results: reporting clinical characteristics and adverse outcomes from an integrated healthcare delivery system. Surg Obes Relat Dis. 2015;11:1119–25. doi:10.1016/j.soard.2015.03.002.CrossRefPubMed Li RA, Fisher DP, Dutta S, O’Brien RM, Ackerson LM, Sorel ME, et al. Bariatric surgery results: reporting clinical characteristics and adverse outcomes from an integrated healthcare delivery system. Surg Obes Relat Dis. 2015;11:1119–25. doi:10.​1016/​j.​soard.​2015.​03.​002.CrossRefPubMed
Metadata
Title
Investing in Obesity Treatment: Kaiser Permanente’s Approach to Chronic Disease Management
Authors
Adam G. Tsai
Trina Histon
W. Troy Donahoo
Shahid Hashmi
Sameer Murali
Peggy Latare
Lajune Oliver
Jennifer Slovis
Sarah Grall
David Fisher
Loel Solomon
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Obesity Reports / Issue 3/2016
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-016-0223-x

Other articles of this Issue 3/2016

Current Obesity Reports 3/2016 Go to the issue

The Obesity Epidemic: Causes and Consequences (A Peeters and A Cameron, Section Editors)

Sleep Duration and Obesity in Adults: What Are the Connections?

Health Services and Programs (AG Tsai, Section Editor)

Improving Obesity Prevention and Management in Primary Care in Canada

The Obesity Epidemic: Causes and Consequences (A Peeters and A Cameron, Section Editors)

The Impact of Obesity in the Workplace: a Review of Contributing Factors, Consequences and Potential Solutions

Health Services and Programs (AG Tsai, Section Editor)

Obesity Treatment in the UK Health System

The Obesity Epidemic: Causes and Consequences (A Peeters and A Cameron, Section Editors)

“Whole-of-Community” Obesity Prevention: A Review of Challenges and Opportunities in Multilevel, Multicomponent Interventions

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.